Surrogate end points and their role in clinical trial. Jaykaran. Indian J Pharmacol. 2009 Feb;41(1):54. doi: 10.4103/0253-7613.48880. PMID: 20177585
When to start antiretroviral therapy. Rhame FS. Curr Infect Dis Rep. 2011 Feb;13(1):60-7. doi: 10.1007/s11908-010-0154-8. PMID: 21308456
rpsftm: An R Package for Rank Preserving Structural Failure Time Models. Allison A, White IR, Bond S. R J. 2017 Dec 04;9(2):342-353. PMID: 29564164
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. Dieterich DT. J Int AIDS Soc. 2006 Jan 19;8(1):16. doi: 10.1186/1758-2652-8-1-16. PMID: 19825136
Impact of Small-N Studies During a Pandemic. Corsello DP, Gotur DB, Carroll CL, Masud FN, Simpson SQ. Chest. 2020 Oct;158(4):1338-1340. doi: 10.1016/j.chest.2020.05.581. Epub 2020 Jun 11. PMID: 32533956
The renaissance of fixed dose combinations: Combivir. Portsmouth SD, Scott CJ. Ther Clin Risk Manag. 2007 Aug;3(4):579-83. PMID: 18472979
A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. Ananworanich J, Kosalaraksa P, Siangphoe U, Engchanil C, Pancharoen C, Lumbiganon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Lange J, Cooper DA, Phanuphak P. AIDS Res Ther. 2008 Oct 28;5:24. doi: 10.1186/1742-6405-5-24. PMID: 18957095